Navigation
The Company
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Contact Us
General Contact
For Healthcare Professionals
Careers
Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (
nab
-Sirolimus)
Home
Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)
Next Post
Previous Post
Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (
nab
-Sirolimus)
April 20, 2019
/
Publications
Like
this post!
Share
the Post
About
the Author
Related
Posts
Correlation of
nab
-sirolimus tumor drug levels and improved tumor suppression in
KRAS G12C
non-small cell lung cancer xenografts treated with
nab
-sirolimus in combination with KRAS inhibitors
Mutational and Biomarker Correlative Analysis of mTOR Pathway Aberrations in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa) Treated With
nab
-Sirolimus: Results From AMPECT, an Open-Label Phase 2 Registration Trial
Solid Tumors Harboring Pathogenic Inactivating Alterations in
TSC1
or
TSC2
Genes (PRECISION 1)
Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement
Patients With Severe Pulmonary Arterial Hypertension Treated With ABI-009,
nab
-Sirolimus, an mTOR Inhibitor: Interim Results From a Phase 1 Clinical Trial
Study-end analysis from AMPECT, an open-label, phase 2 registration trial of patients with advanced malignant PEComatreated with
nab
-sirolimus, showing durability of response and long-term safety
Aadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARROâ„¢ for the Treatment of Advanced Malignant PEComa
Read More
Richard Maroun, JD
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.